Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
The present vaccine against influenza virus has the inevitable risk of antigenic discordance between the vaccine and the circulating strains, which diminishes vaccine efficacy. This necessitates new approaches that provide broader protection against influenza. Here we designed a vaccine using the hy...
Saved in:
Published in | Nature immunology Vol. 20; no. 3; pp. 362 - 372 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
01.03.2019
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present vaccine against influenza virus has the inevitable risk of antigenic discordance between the vaccine and the circulating strains, which diminishes vaccine efficacy. This necessitates new approaches that provide broader protection against influenza. Here we designed a vaccine using the hypervariable receptor-binding domain (RBD) of viral hemagglutinin displayed on a nanoparticle (np) able to elicit antibody responses that neutralize H1N1 influenza viruses spanning over 90 years. Co-display of RBDs from multiple strains across time, so that the adjacent RBDs are heterotypic, provides an avidity advantage to cross-reactive B cells. Immunization with the mosaic RBD–np elicited broader antibody responses than those induced by an admixture of nanoparticles encompassing the same set of RBDs as separate homotypic arrays. Furthermore, we identified a broadly neutralizing monoclonal antibody in a mouse immunized with mosaic RBD–np. The mosaic antigen array signifies a unique approach that subverts monotypic immunodominance and allows otherwise subdominant cross-reactive B cell responses to emerge.
Antigenic variation of influenza A viruses necessitates the annual reformulation of vaccines. Kanekiyo et al. develop a mosaic nanoparticle vaccine against influenza virus that is able to elicit neutralizing antibodies that span nearly 100 years of variation of influenza A virus. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 M.K. and B.S.G. conceptualized and devised studies. M.K. designed immunogens. M.K., R.A.G., H.M.Y. and S.B.B. performed animal studies; M.G.J. crystallized and solved Fab structure; J.R.G. and A.K.H. determined cryo-EM structure; S.F.A., A.K.W., B.E.F., D.R.A. and M.S.P. performed FACS and single-cell PCR; M.K., R.A.G., S.F.A. and H.M.Y. produced and characterized proteins; A.C. made viruses by reverse genetics; R.A.G., H.M.Y., K.L., E.S.Y. and W.-P.K. performed virus neutralization assays; I.S.G. performed mathematical simulations; Y.T. and U.B. performed EM experiments; H.A. performed challenge studies; K.L.Z. and J.E.L. conducted clinical trials and provided human samples; M.K., M.G.J., R.A.G., J.R.G., S.F.A., H.M.Y., A.K.W., A.K.H., R.A.K., P.D.K., A.B.M., J.R.M. and B.S.G. analyzed data; M.K. and B.S.G. wrote paper with input from all authors. Author contributions |
ISSN: | 1529-2908 1529-2916 1529-2916 |
DOI: | 10.1038/s41590-018-0305-x |